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Critical limb ischemia (CLI) remains a major unmet public
health concern in the United States. Despite therapies that include
bypass surgery and a vast array of endovascular options, there
remain a substantial number of patients that because of distal
extent of disease, absent autogenous conduit, or associated co
morbidities do not have revascularization options. These patients
are left with poor quality of life and the frequent need for major
amputation. To date, several pharmacologic and biologic therapies
have demonstrated the ability to improve limb perfusion but have
not as yet demonstrated a beneficial effect on the clinically mean-
ingful endpoint of amputation-free survival. As such there remains
a dire need for an effective minimally invasive therapy for the
no-option or poor-option patient with CLI.
The authors have described a highly innovative procedure that
could potentially meet this need. They have developed a minimally
invasive technique to temporarily perfuse the ischemic extremity at
supra-physiologic blood pressures that are isolated to the affected
extremity. This technique, described as Hypertensive Extracorpo-
real Limb Hyperperfusion (HELP), can be developed for chronic
use. The appeal of HELP is that it may have an acute beneficial
effect on perfusion as well as a delayed effect through increased
formation of collateral blood vessels due to the temporary eleva-convincing preclinical data that perfusion improves with HELP in
a large animal hind limb ischemia model and have provided evi-
dence of feasibility in a small safety study in no-option patients.
The next step in the development of this technique would be
to perform a clinical trial. Unfortunately this is a significant hurdle
in the “no-option” CLI patient population. It is difficult to con-
duct trials in patients with CLI because of patient heterogeneity
and frequent associated co-morbidities. This group of patients that
may present with rest pain through extensive tissue loss and adverse
events are common in such trials. Currently available surrogate
endpoints to measure limb perfusion are not accurate. Though the
natural history of untreated CLI is poor, adjudicated outcomes
data in this patient population are lacking. The need for a control
group to truly assess the efficacy of this therapy further complicates
study design and patient recruitment. In the current study, the few
patients treated by the authors had very different vascular pathol-
ogies and proof of efficacy is lacking.
The authors are to be congratulated for bringing forward an
exciting concept for the treatment of a cohort of patients with few
options and a poor quality of life. The next step, to conduct a
well-designed clinical trial to demonstrate proof of efficacy will be
equally challenging.
